Show simple item record

dc.contributor.authorGumus, Mahmut
dc.contributor.authorBilici, Ahmet
dc.contributor.authorOdabas, Hatice
dc.contributor.authorUstaalioglu, Bala Basak Oven
dc.contributor.authorKandemir, Nurten
dc.contributor.authorDemirci, Umut
dc.contributor.authorCihan, Sener
dc.contributor.authorBayoglu, Ibrahim Vedat
dc.contributor.authorOzturk, Turkan
dc.contributor.authorTurkmen, Esma
dc.contributor.authorUrakci, Zurat
dc.contributor.authorSeker, Mehmet Metin
dc.contributor.authorGunaydin, Yusuf
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorTuran, Nedim
dc.contributor.authorSevinc, Alper
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T09:40:54Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T09:40:54Z
dc.date.issued2017
dc.identifier.issn0724-4983
dc.identifier.issn1433-8726
dc.identifier.urihttps://dx.doi.org/10.1007/s00345-016-1964-6
dc.identifier.urihttps://hdl.handle.net/20.500.12418/6738
dc.descriptionWOS: 000404154000013en_US
dc.descriptionPubMed ID: 27812752en_US
dc.description.abstractBackground Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable treatment options for these patients, but there is no uniform consensus. The purpose of this study was to compare outcomes of active surveillance with adjuvant chemotherapy. Methods A total of 201 patients with CS I NSGCT after orchiectomy were included. Outcomes of active surveillance and adjuvant chemotherapy were retrospectively analyzed. The prognostic significance of risk factors for survival and relapse was evaluated. Results Of the 201 patients, 110 (54.7%) received adjuvant chemotherapy, while the remaining 91 patients (45.3%) underwent surveillance. Relapses were significantly higher for patients underwent surveillance compared to adjuvant chemotherapy group (18.3 vs. 1.2%, p < 0.001). The 5-year relapse-free survival (RFS) rate for patients who were treated with adjuvant chemotherapy was significantly better than those of patients underwent surveillance (97.6 vs. 80.8%, respectively; p < 0.001). Univariate analysis showed that the presence of LVI (p = 0.01) and treatment option (p < 0.001) were prognostic factors for RFS and pT stage (p = 0.004) and invasion of rete testis (p = 0.004) and the presence of relapse (p < 0.001) were significant prognostic factors for OS. Multivariate analysis revealed that the treatment strategy was an independent prognostic factor for RFS (p < 0.001, HR 0.54). A logistic regression analysis demonstrated that treatment options (p = 0.031), embryonal carcinoma (EC) > 50% (p = 0.013) and tumor diameter (p = 0.016) were found to be independent factors for predicting relapse. Conclusion Our results indicate that adjuvant chemotherapy is associated with improved RFS compared with surveillance for CS I NSGCT patients. Moreover, the treatment strategy is an important prognostic indicator for RFS and a predictive factor for relapse. Although adjuvant chemotherapy seems to be a suitable treatment for patients with risk factors for relapse, surveillance is still preferred management option.en_US
dc.language.isoengen_US
dc.publisherSPRINGERen_US
dc.relation.isversionof10.1007/s00345-016-1964-6en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectStage Ien_US
dc.subjectNonseminomatous germ cell tumoren_US
dc.subjectTesticular canceren_US
dc.subjectChemotherapyen_US
dc.subjectSurveillanceen_US
dc.titleOutcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumorsen_US
dc.typearticleen_US
dc.relation.journalWORLD JOURNAL OF UROLOGYen_US
dc.contributor.department[Gumus, Mahmut] Istanbul Medeniyet Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- [Bilici, Ahmet] Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- [Odabas, Hatice] Dr Lutfi Kirdar Kartal Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Ustaalioglu, Bala Basak Oven] Haydarpasa Numune Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Kandemir, Nurten] Ankara Onkol Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey -- [Demirci, Umut] Ataturk Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey -- [Cihan, Sener] Okmeydani Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Bayoglu, Ibrahim Vedat] Izmir Ataturk Educ & Res Hosp, Dept Med Oncol, Izmir, Turkey -- [Ozturk, Turkan] Karadeniz Univ, Fac Med, Dept Med Oncol, Trabzon, Turkey -- [Turkmen, Esma] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey -- [Urakci, Zurat] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkey -- [Seker, Mehmet Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Gunaydin, Yusuf] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey -- [Selcukbiricik, Fatih] Koc Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- [Turan, Nedim] Malatya State Hosp, Dept Med Oncol, Malatya, Turkey -- [Sevinc, Alper] Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey -- [Bilici, Ahmet] Tem Avrupa Otoyolu,Goztepe Cikisi 1, TR-34214 Istanbul, Turkeyen_US
dc.contributor.authorIDDEMIRCI, UMUT -- 0000-0002-4833-6721en_US
dc.identifier.volume35en_US
dc.identifier.issue7en_US
dc.identifier.endpage1110en_US
dc.identifier.startpage1103en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record